Physician profile
Anthony V Perry
NPI 1619976313
$7,293.27
in general payments reported to CMS, 2019-2025
54 companies · $1,019 in 2025
The $1,019 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $839 · 2020: $771 · 2021: $1,059 · 2022: $1,159 · 2023: $1,408 · 2024: $1,039 · 2025: $1,019.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,466.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,466.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,071.41 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $839.42 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $482.20 | 2019-2024 | Mounjaro, Jardiance, Emgality |
| Abbvie INC. | $429.91 | 2019-2025 | |
| Pfizer INC. | $423.83 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $411.57 | 2019-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $380.13 | 2020-2025 | Ofev, Jardiance, Tradjenta |
| Indivior INC. | $379.69 | 2020-2025 | Sublocade |
| Merck Sharp & Dohme LLC | $298.04 | 2019-2024 | Verquvo, Dificid, Steglatro |
| Novartis Pharmaceuticals Corporation | $298.03 | 2019-2024 | |
| Amarin Pharma, INC. | $224.03 | 2019-2022 | |
| Exact Sciences Corporation | $143.34 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $126.84 | 2020-2024 | Trelegy Ellipta |
| Abiomed | $124.31 | 2023 | Impella |
| Sunovion Pharmaceuticals INC. | $116.43 | 2021-2022 |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Perry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.